{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:01:19Z","timestamp":1784646079940,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13584-0","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:37:02Z","timestamp":1779727022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and safety of novel oral polio vaccine type 2 (nOPV2) in pediatric populations: a systematic review and Bayesian meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Jos\u00e9 Lu\u00eds","family":"Boene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Rocha","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella Chiara","family":"Carpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Muhawenimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Helena","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilsa","family":"de Deus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilson Fernando Loforte","family":"Bauhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"12","key":"13584_CR1","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/14760584.2017.1393337","volume":"16","author":"JL Goodson","year":"2017","unstructured":"Goodson JL, Alexander JP, Linkins RW, Orenstein WA. Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach. Expert Rev Vaccines. 2017;16(12):1203\u201316. https:\/\/doi.org\/10.1080\/14760584.2017.1393337.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"13584_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-virology-101416-041749","volume":"5","author":"O Kew","year":"2018","unstructured":"Kew O, Pallansch M. Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication. Annual Rev Virol. 2018;5(1):427\u201351. https:\/\/doi.org\/10.1146\/annurev-virology-101416-041749.","journal-title":"Annual Rev Virol"},{"key":"13584_CR3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6718a4","author":"F Khan","year":"2018","unstructured":"Khan F, Datta SD, Vertefeuille JF, Jorba J, Wassilak SGF, Burns CC, Quddus A. Progress toward polio eradication\u2014worldwide, January 2016\u2013March 2018. MMWR Morb Mortal Wkly Rep. 2018;67(18):524-528 https:\/\/doi.org\/10.15585\/mmwr.mm6718a4."},{"issue":"5","key":"13584_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/erv.12.28","volume":"11","author":"V Pliaka","year":"2012","unstructured":"Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines. 2012;11(5):609\u201328. https:\/\/doi.org\/10.1586\/erv.12.28.","journal-title":"Expert Rev Vaccines"},{"issue":"45","key":"13584_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.15585\/mmwr.mm6845a4","volume":"68","author":"J Jorba","year":"2019","unstructured":"Jorba J, Zhao K, Pallansch MA, Henderson E, Burns CC, Sutter R, Quddus A, Iber J, Diop OM, Wassilak SGF, Wenger J, Vertefeuille JF. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1024\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm6845a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"13584_CR6","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6530a4","author":"A Etsano","year":"2016","unstructured":"Etsano A, Enemaku O, Nnadi C, Nganda GW, Usman S, Ohuabunwo C, Iber J, Jorba J, Adeniji A, Wiesen E, Shuaib F, Damisa E. Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission\u2014Nigeria, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(30):770-773 https:\/\/doi.org\/10.15585\/mmwr.mm6530a4."},{"issue":"4","key":"13584_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/pathogens13040273","volume":"13","author":"FD Kurji","year":"2024","unstructured":"Kurji FD, Bandyopadhyay AS, Zipursky S, Cooper LV, Gast C, Toher M, Clemens R, Clemens SAC, Prasad R, Azhari A. Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency. Pathogens (Basel Switzerland). 2024;13(4):273. https:\/\/doi.org\/10.3390\/pathogens13040273.","journal-title":"Pathogens (Basel Switzerland)"},{"key":"13584_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41564-025-02219-w","volume":"11","author":"P Tushabe","year":"2026","unstructured":"Tushabe P, Majumdar M, Carlyle S, et al. Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda. Nat Microbiol. 2026;11:406\u201314. https:\/\/doi.org\/10.1038\/s41564-025-02219-w.","journal-title":"Nat Microbiol"},{"issue":"9","key":"13584_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/vaccines12090953","volume":"12","author":"LR Mej\u00eda","year":"2024","unstructured":"Mej\u00eda LR, Mendez LP, R\u00fcttimann RW, Gast C, Bandyopadhyay AS. Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Vaccinated Children and Vaccine-Na\u00efve Infants: A Phase 4 Study. Vaccines. 2024;12(9):953. https:\/\/doi.org\/10.3390\/vaccines12090953.","journal-title":"Vaccines"},{"issue":"10432","key":"13584_CR10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(23)02844-1","volume":"403","author":"M Ochoge","year":"2024","unstructured":"Ochoge M, Futa AC, Umesi A, Affleck L, Kotei L, Daffeh B, Saidy-Jah E, Njie A, Oyadiran O, Edem B, Jallow M, Jallow E, Donkor SA, Tritama E, Abid T, Jones KAV, Mainou BA, Konz JO, Fix A, Gast C, Clarke E. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <\u20095 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial. Lancet (London England). 2024;403(10432):1164\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(23)02844-1.","journal-title":"Lancet (London England)"},{"key":"13584_CR11","doi-asserted-by":"publisher","unstructured":"Longley AT, Nsubuga F, Gilani Z, Tobolowsky FA, Kisakye A, Greene SA, Ampeire I, Ssennono VF, Gyasi SO, Ntale I, Bammeke P, Stewart B, Ndagije HB, Kyabayinze DJ, Gidudu JF. Safety of nOPV2 administered during a supplementary immunisation activity in Uganda, 2022: data triangulation from a prospective cohort event monitoring programme and vaccine safety surveillance reports. Lancet Global health. 2025;S2214\u2013109X2500110\u2013X. https:\/\/doi.org\/10.1016\/S2214-109X(25)00110-X. Advance online publication.","DOI":"10.1016\/S2214-109X(25)00110-X"},{"key":"13584_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"13584_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ (Clinical Res ed)"},{"key":"13584_CR14","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"issue":"10268","key":"13584_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","volume":"397","author":"X S\u00e1ez-Llorens","year":"2021","unstructured":"S\u00e1ez-Llorens X, Bandyopadhyay AS, Gast C, Leon T, DeAntonio R, Jimeno J, Caballero MI, Aguirre G, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, Fix A, Konz J, Clemens R, Clemens C, S. A., R\u00fcttimann R. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet (London England). 2021;397(10268):27\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(20)32540-X.","journal-title":"Lancet (London England)"},{"issue":"10371","key":"13584_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(22)02397-2","volume":"401","author":"K Zaman","year":"2023","unstructured":"Zaman K, Bandyopadhyay AS, Hoque M, Gast C, Yunus M, Jamil KM, Mainou BA, Konopka-Anstadt JL, Hendley WS, Vincent A, Clemens R, Clemens SAC, Ross AG, Clemens JD, Tritama E. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet (London England). 2023;401(10371):131\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(22)02397-2.","journal-title":"Lancet (London England)"},{"issue":"9","key":"13584_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(23)00139-1","volume":"23","author":"AL Wilkinson","year":"2023","unstructured":"Wilkinson AL, Zaman K, Hoque M, Estivariz CF, Burns CC, Konopka-Anstadt JL, Mainou BA, Kovacs SD, An Q, Lickness JS, Yunus M, Snider CJ, Zhang Y, Coffee E, Abid T, Wassilak SGF, Pallansch MA, Oberste MS, Vertefeuille JF, Anand A. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis. 2023;23(9):1062\u201371. https:\/\/doi.org\/10.1016\/S1473-3099(23)00139-1.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"13584_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1473-3099(23)00519-4","volume":"24","author":"L Rivera Mej\u00eda","year":"2024","unstructured":"Rivera Mej\u00eda L, Pe\u00f1a M\u00e9ndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, Rosario N, Zhang Y, Mainou BA, Jimeno J, Aguirre G, R\u00fcttimann R. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. Lancet Infect Dis. 2024;24(3):275\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(23)00519-4.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"13584_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1473-3099(23)00631-X","volume":"24","author":"AO Bashorun","year":"2024","unstructured":"Bashorun AO, Kotei L, Jawla O, Jallow AF, Saidy AJ, Kinteh MA, Kujabi A, Jobarteh T, Kanu FJ, Donkor SA, Ezeani E, Fofana S, Njie M, Ceesay L, Jafri B, Williams A, Jeffries D, Kotanmi B, Mainou BA, Ooko M, Clarke E. Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study. Lancet Infect Dis. 2024;24(4):417\u201326. https:\/\/doi.org\/10.1016\/S1473-3099(23)00631-X.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13584-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13584-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13584-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:02:16Z","timestamp":1784642536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13584-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13584"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13584-0","relation":{"references":[{"id-type":"doi","id":"10.15585\/mmwr.mm6718a4","asserted-by":"subject"},{"id-type":"doi","id":"10.15585\/mmwr.mm6530a4","asserted-by":"subject"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review and meta-analysis based exclusively on data from previously published studies and did not involve direct interaction with human participants or the collection of new individual-level data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1375"}}